Shilpa Medicare Q2 Net Profit Rises 80% to ₹79 Crore as Revenue Grows 43%

Shilpa Medicare reported a consolidated net profit of ₹79 crore for the September quarter, up 79.5% from ₹44 crore a year earlier, on revenue of ₹529 crore. CNBC TV18 reported that revenue rose 43% from ₹370 crore in the same quarter last year, according to the company's exchange filing.

Shilpa Medicare's Q2 Profit and Revenue Growth

Shilpa Medicare is an Indian pharmaceutical manufacturer of oncology active ingredients, formulations, biologics, peptides and specialty polymers, offering contract development and manufacturing services to drugmakers in more than 100 countries.

EBITDA rose 30.3% to ₹142 crore from ₹109 crore, while the EBITDA margin declined 250 basis points to 27% from 29.5%. In its specialty CDMO business, the company said commercial supplies to a European customer are expected to start in the second half of FY27. It also reported a strong order book in peptides and said its semaglutide drug master file is ready for filing.

Shilpa Medicare is adding one of India's largest solid-phase synthesis capacities, designed for GLP-1, high-potency active pharmaceutical ingredients and CDMO work. In polymers, it onboarded a new US customer and received initial orders, with execution expected by the second half of FY27. A new customer in Japan is expected to begin commercial supplies by the end of FY27.

Managing Director Vishnukant Bhutada said the novel finished dosage form portfolio is progressing, with niche launches lined up through FY27 and beyond. He also cited an expanded partnership with Orion Corporation covering Shilpa Medicare's Nivolumab biosimilar in Europe, under which the company serves as development and supply partner. "With strong first-half momentum, a maturing pipeline, and a sharpened strategic focus, we are well positioned to deliver a stronger FY27," Bhutada said.

Shilpa Medicare's Full-Year Revenue Base

According to akta.pro company records, Shilpa Medicare's full-year revenue for FY2026, ended March 2026, was ₹1,538.87 crore, growth of 19.62% year over year. Full-year FY2026 net profit was ₹243.33 crore, a rise of 210.81%. The same records show Q4 FY2026 revenue of ₹436.99 crore, up 32.09% year over year.

Europe Approval and Earlier Quarter Results

In October 2026, Shilpa Medicare received GMP certification from AGES Austria for its Jadcherla Unit 4 facility, following an inspection from July 27 to July 30, 2026, ScanX reported. The approval covers sterile injections and non-sterile tablets and capsules for export to Europe and other markets.

In September 2026, NDTV Profit reported that Shilpa Medicare's Q1FY27 revenue was ₹469 crore, up 43% year over year, after its stock gained 238% in 2026. The Indian Express reported in August 2026 that the company had posted four consecutive quarters of record revenue and EBITDA, driven by growth across APIs, formulations, peptides, biologics and CDMO.

Shilpa Medicare's European Supply Timeline

The company said commercial supplies to its European CDMO customer are expected to commence in the second half of FY27. Initial orders from its new US polymer customer are expected to be executed by the second half of FY27, and commercial supplies to its new Japanese customer are expected to begin by the end of FY27.